You are here

  • Home
  • Archive
  • Volume 19, Issue 2
  • Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature

Article Text

Article menu
Download PDFPDF
Original Articles: Uterine Cancer
Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature
  1. Frédéric Amant, MD, PhD*,
  2. An Coosemans, MD*,
  3. Vincent Renard, MD†,
  4. Els Everaert, MD‡ and
  5. Ignace Vergote, MD, PhD*
  1. * Division of Gynecological Oncology, Leuven Cancer Institute (LKI), UZ Gasthuisberg, Katholieke Universiteit Leuven;
  2. † Department of Medical Oncology, St-Lucas Ziekenhuis Gent; and
  3. ‡ Department of Medical Oncology, AZ Nikolaas-Sint-Niklaas, Belgium.
  1. Address correspondence and reprint requests to Frédéric Amant, Division of Gynecological Oncology, Department of Obstetrics and Gynecology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Herestraat 49, 3000 Leuven, Belgium. E-mail: Frederic.amant{at}uz.kuleuven.ac.be.

Abstract

Abstract The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which 1 had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of 11 patients with a clinical benefit in 7 (64%) of 11 patients. These results on the use of ET-743 in uterine sarcoma patients support the conductance of larger trials.

  • Uterine
  • Leiomyosarcoma
  • Yondelis
  • ET-743
  • Trabectedin
  • Sarcoma

https://doi.org/10.1111/IGC.0b013e31819c0f59

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Frédéric Amant is clinical researcher, and An Coosemans is an Aspirant of the Fund for Scientific Research-Flanders (FWO-Vlaanderen).